Global Blood Therapeutics beats by $0.06 (28.85 -0.60)
- Reports Q2 (Jun) loss of $0.55 per share, $0.06 better than the Capital IQ Consensus of ($0.61); co did not report any revs
- "We have already completed dosing in this new cohort, which we expect will generate pharmacokinetic data to help support GBT440 dose selection in children as young as 9 months of age. Looking forward, we plan to provide additional details on our pediatric program at the American Society of Hematology Annual Meeting. We continue to enroll patients in the Phase 3 HOPE Study, and in our hypoxemia program we plan to report results in the fourth-quarter of this year."